company background image
OSL logo

OncoSil Medical CHIA:OSL Stock Report

Last Price

AU$0.007

Market Cap

AU$23.8m

7D

16.7%

1Y

-46.1%

Updated

12 Jul, 2024

Data

Company Financials

OSL Stock Overview

A medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide.

OSL fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

OncoSil Medical Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for OncoSil Medical
Historical stock prices
Current Share PriceAU$0.007
52 Week HighAU$0.013
52 Week LowAU$0.004
Beta0.53
11 Month Change55.56%
3 Month Change16.67%
1 Year Change-46.15%
33 Year Change-88.33%
5 Year Change-87.04%
Change since IPO-91.95%

Recent News & Updates

Recent updates

Shareholder Returns

OSLAU Life SciencesAU Market
7D16.7%7.8%0.7%
1Y-46.1%-1.2%9.2%

Return vs Industry: OSL underperformed the Australian Life Sciences industry which returned -1.2% over the past year.

Return vs Market: OSL underperformed the Australian Market which returned 9.2% over the past year.

Price Volatility

Is OSL's price volatile compared to industry and market?
OSL volatility
OSL Average Weekly Movement25.6%
Life Sciences Industry Average Movement8.9%
Market Average Movement8.4%
10% most volatile stocks in AU Market16.9%
10% least volatile stocks in AU Market3.3%

Stable Share Price: OSL's share price has been volatile over the past 3 months.

Volatility Over Time: OSL's weekly volatility (26%) has been stable over the past year, but is still higher than 75% of Australian stocks.

About the Company

FoundedEmployeesCEOWebsite
2005n/aNigel Langewww.oncosil.com.au

OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.

OncoSil Medical Limited Fundamentals Summary

How do OncoSil Medical's earnings and revenue compare to its market cap?
OSL fundamental statistics
Market capAU$23.79m
Earnings (TTM)-AU$11.71m
Revenue (TTM)AU$1.30m

18.3x

P/S Ratio

-2.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
OSL income statement (TTM)
RevenueAU$1.30m
Cost of RevenueAU$1.87m
Gross Profit-AU$573.73k
Other ExpensesAU$11.13m
Earnings-AU$11.71m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.0034
Gross Margin-44.18%
Net Profit Margin-901.58%
Debt/Equity Ratio0%

How did OSL perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.